Aevi Genomic Medicine Inc
GNMX
GNMX was delisted on the 3rd of February, 2020.
28 hedge funds and large institutions have $15.4M invested in Aevi Genomic Medicine Inc in 2014 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 14 increasing their positions, 3 reducing their positions, and 2 closing their positions.
367% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 3
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
30% more capital invested
Capital invested by funds: $11.8M → $15.4M (+$3.59M)
8% more funds holding
Funds holding: 26 → 28 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$2M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$468K |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$393K |
| 4 |
Morgan Stanley
New York
|
+$328K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$312K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Legal & General Group
London,
United Kingdom
|
-$2.15M |
| 2 |
PSI
Pinnacle Summer Investments
Fairfax,
Virginia
|
-$31K |
| 3 |
LPL Financial
San Diego,
California
|
-$28.8K |
| 4 |
CD
Carl Domino
West Palm Beach,
Florida
|
-$8.96K |
GNMX Hedge Fund Activity: Q1 2014 in Review
28 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Aevi Genomic Medicine Inc (GNMX) for Q1 2014, worth a combined $15.4M — up 30% from $11.8M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new GNMX positions and 2 closed out — a net gain of 2 holders — while 14 added to existing stakes and 3 trimmed.
The largest buyer was Baillie Gifford & Co, adding an estimated $2M. The largest seller was Legal & General Group, cutting an estimated $2.15M.
- 28 institutional investors held Aevi Genomic Medicine Inc (GNMX) as of Q1 2014, up from 26 in Q4 2013.
- Funds reported $15.4M of Aevi Genomic Medicine Inc stock for Q1 2014, up 30% quarter-over-quarter.
- 4 funds opened new Aevi Genomic Medicine Inc positions in Q1 2014 and 2 closed out, a net change of +2 holders.
- The largest Aevi Genomic Medicine Inc buyer in Q1 2014 was Baillie Gifford & Co, an estimated $2M added.
- The largest Aevi Genomic Medicine Inc seller in Q1 2014 was Legal & General Group, an estimated $2.15M sold.
Based on aggregated 13F filings for Q1 2014.